


ONLINE SUPPLEMENTAL MATERIALS:

Supplemental Figure S1: Histograms of weight-adjusted Propofol induction dose within each Age X ASA Physical Status category.

(Vertical Dotted Line demonstrates the Upper Limit of Typical FDA-Label Dose Range.)



Supplemental Table S2:

Absolute and Weight-Adjusted Propofol Induction Dose by Age and ASA Physical Status.						
Age Bin	ASA Physical Status Score	Mean Absolute Dose (mg)	SD	Weight-Adjusted Dose (mg/Kg)	SD	N
65 - 69 Years	1	154.4	46.8	2.1	0.7	1489
	2	158.9	47.3	2.0	0.6	45755
	3	153.2	48.6	1.8	0.6	73429
	4	118.1	52.5	1.4	0.7	9743
70 - 74 Years	1	143.8	46.3	2.0	0.6	604
	2	148.6	45.5	1.9	0.6	28286
	3	142.8	47.3	1.7	0.6	59381
	4	109.7	49.3	1.3	0.6	8788
75 - 79 Years	1	137.7	42.6	1.9	0.6	233
	2	136.8	44.3	1.8	0.6	15372
	3	131.2	45.3	1.7	0.6	41901
	4	103.2	47.0	1.3	0.6	7057
80 or Over Years	1	117.4	43.0	1.8	0.6	95
	2	116.9	42.3	1.7	0.6	9806
	3	109.5	42.0	1.5	0.6	39815
	4	88.0	41.5	1.2	0.6	9007

Supplemental Table S3: Multivariable analysis evaluating the association of demographic and perioperative factors with total induction dose of propofol (mg).

Variable	Beta (SE)	p-Value
Gender, Female vs Male	-6.493 (0.2665)	<0.0001
Weight, kg	0.6965 (0.0185)	<0.0001
Height, cm	0.1225 (0.0215)	<0.0001
Van Walraven/ Elixhauser Index	-0.2593 (0.0106)	<0.0001
Baseline MAP	0.1959 (0.0062)	<0.0001
Duration Anesthesia Start to End (min)	-0.0132 (0.0008)	<0.0001
Emergency vs. Non-Emergency	-6.656 (0.4148)	<0.0001
Anesthesia Base Units (>5 Base Units)	-0.5117 (0.2498)	0.0405
Year of Surgery		<0.0001*
2015	0.9401 (0.3223)	0.0035
2016	1.8296 (0.3178)	<0.0001
2017	1.9228 (0.3133)	<0.0001
2018	4.4726 (0.3134)	<0.0001
2014	Ref	
Age		<0.0001*
70 - 74	-8.9986 (2.9998)	0.0027
75 - 79	-15.6615 (4.6971)	0.0009
80 or Over	-37.7097 (6.1809)	<0.0001
65 - 69	Ref	
ASA PS		<0.0001*
2	-1.5872 (1.6401)	0.3332
3	-8.0289 (1.6342)	<0.0001
4	-31.1669 (1.7076)	<0.0001
1	Ref	
Age x ASA PS		<0.0001*
70 – 74 x 2	1.4154 (3.0288)	0.6403
70 – 74 x 3	1.0215 (3.0119)	0.7345
70 – 74 x 4	3.9536 (3.0824)	0.1996
70 – 74 x 1	Ref	
75 – 79 x 2	-1.0933 (4.7245)	0.817
75 – 79 x 3	-0.0468 (4.7066)	0.9921
75 – 79 x 4	5.7027 (4.7569)	0.2306
75 – 79 x 1	Ref	
80 or Over x 2	6.6702 (6.2085)	0.2827
80 or Over x 3	7.2738 (6.1876)	0.2398
80 or Over x 4	20.0658 (6.2198)	0.0013
80 or Over x 1	Ref	
BMI		<0.0001*
Class I obesity (BMI 30 to <35)	-1.0394 (0.561)	0.0639
Class II obesity (BMI 35 to <40)	-2.0145 (0.8245)	0.0146
Class III obesity (BMI ≥40)	-2.2338 (1.1311)	0.0483
Overweight (BMI (25 to <30)	0.4425 (0.3303)	0.1804
Underweight (BMI <18.5)	-4.1282 (1.0591)	0.0001

Normal weight (BMI 18.5 to <25)	Ref	
Coronary Artery Disease, Yes	-7.4996 (0.2252)	<0.0001
CKD Severity		<0.0001*
Stage 2	-0.1111 (0.2539)	0.6619
Stage 3a	-1.5792 (0.3112)	<0.0001
Stage 3b	-2.8881 (0.3909)	<0.0001
Stage 4	-4.4614 (0.5917)	<0.0001
Stage 1	Ref	
Preoperative Anemia		<0.0001*
Mild	-4.0199 (0.199)	<0.0001
Moderate to Severe	-9.3431 (0.3015)	<0.0001
Normal	Ref	
Neuraxial Anesthesia, Yes	-2.783 (0.7852)	0.0004
Academic vs. Community Institution	1.5246 (4.2345)	0.7188
Surgery Subspecialty		<0.0001*
Cardiothoracic	-26.5031 (0.4327)	<0.0001
Medical - gastroenterology	-14.6539 (0.5669)	<0.0001
Medical Subspecialty	-9.7604 (0.6808)	<0.0001
Neurosurgery	0.4389 (0.3349)	0.1900
Gynecology	-0.2954 (0.4458)	0.5076
Ophthalmology	-5.9306 (1.4459)	<0.0001
Oral/Maxillofacial/Otolaryngology	1.5048 (0.4119)	0.0003
Orthopedics	-4.7875 (0.2995)	<0.0001
Other	-3.0173 (0.4261)	<0.0001
Plastics/Maxillofacial	2.7461 (0.8144)	0.0007
Radiology	2.3929 (0.8373)	0.0043
Thoracic	-5.9303 (0.4339)	<0.0001
Transplant	-3.2196 (1.4761)	0.0292
Trauma	-7.446 (1.0079)	<0.0001
Urology	4.7804 (0.3837)	<0.0001
Vascular	-10.3245 (0.5054)	<0.0001
General	Ref	
Ethnicity		<0.0001*
Hispanic	1.4855 (0.7291)	0.0416
Unknown	3.1516 (0.6092)	<0.0001
Non-Hispanic	Ref	
Race		<0.0001*
Black	0.9521 (0.3529)	0.007
Unknown/other	-3.9853 (0.4265)	<0.0001
White	Ref	
Predicted Frailty		<0.0001*
High	-6.0703 (0.927)	<0.0001
Intermediate	-2.5692 (0.2992)	<0.0001
Low	Ref	

Note: Individual institution was treated as a random effect to account for possible similarity among patients cared for at each institution. A total of **228492** patients were included in the analysis

*: Type III test p-value

Supplemental Figure S4: Histogram of absolute propofol dose in milligrams (mg) for the dataset, demonstrating discontinuous clustering of propofol induction doses at 50mg increments.

